The plasma concentration profiles of levocarnitine after a slow 3 minute intravenous bolus dose of 20 mg/kg of Levocarnitine were described by a two-compartment model
"At the moment, Namibia and Kenya are on our shortlist
Typical trial exclusion criteria for retatrutide studies, consistent with those applied to similar investigational and licensed medicines in this class, have included: pregnancy or breastfeeding (with active contraception requirements during participation)
References Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D
It also says concurrent use with other medications, especially those affecting lipid metabolism, requires medical oversight
Clinics providing compounds without ongoing monitoring prioritize convenience over safety